FIELD: chemistry.
SUBSTANCE: group of inventions relates to a compound of formula A''
or pharmaceutically acceptable salts thereof, as well as a pharmaceutical composition, and a medicinal agent containing same, and use for preparing a medicinal agent for treating autoimmune diseases by inhibition of Janus kinase.
EFFECT: improved compared to (1-(2-hydroxy-ethanesulphonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrazol-1-yl]-azetidin-3-yl)-acetonitrile selectivity with respect to inhibition of JAK enzymes.
11 cl, 2 dwg, 3 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837548C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837216C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837316C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837533C1 |
NOVEL PYRROLOPYRIMIDINE DERIVATIVES | 2024 |
|
RU2837215C1 |
{3-[(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)AZOLYL]AZETIDIN-3-YL} ACETONITRILES AS JANUS KINASE INHIBITORS | 2015 |
|
RU2601410C1 |
METHOD OF PRODUCING 2-[1-ETHYLSULPHONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE | 2024 |
|
RU2835441C1 |
METHOD OF PRODUCING 2-[1-ETHYLSULPHONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE | 2024 |
|
RU2835443C1 |
METHOD OF PRODUCING 2-[1-ETHYLSULPHONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE | 2024 |
|
RU2835445C1 |
TREATMENT OF HYDRADENITIS WITH JAK INHIBITORS | 2020 |
|
RU2805595C1 |
Authors
Dates
2025-03-27—Published
2024-12-17—Filed